How we improved the treatment of Hodgkin lymphoma

City of Hope launches AI tool to reduce burden of cancer care

City of Hope is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials, and empower breakthrough research.

June 27, 2025

Vol.51 No.25

Clinical Roundup

Duvelisib + romidepsin combination effective for T-cell lymphoma patients, Mass General Brigham study shows

Relapsed/refractory peripheral and cutaneous T-cell lymphomas are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell transplants, but the disease needs to be brought under control before patients can undergo this treatment.

June 27, 2025

Vol.51 No.25

From “undruggable” target to clinical potential: The journey of AOH1996

When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

City of Hope has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health within the U.S. Department of Health and Human Services. The grant will help City of Hope create a biomap of tumor changes that cause immunotherapy resistance in advanced or metastatic non-small cell lung cancer.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Drugs & Targets

FDA approves tafasitamab-cxix for r/r follicular lymphoma

FDA has approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

June 20, 2025

Vol.51 No.24

How we improved the treatment of Hodgkin lymphoma

YOU MAY BE INTERESTED IN

City of Hope launches AI tool to reduce burden of cancer care

Duvelisib + romidepsin combination effective for T-cell lymphoma patients, Mass General Brigham study shows

From “undruggable” target to clinical potential: The journey of AOH1996

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

FDA approves tafasitamab-cxix for r/r follicular lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login